TXMD - TherapeuticsMD, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.55
+0.13 (+2.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.42
Open5.46
Bid0.00 x 900
Ask0.00 x 27000
Day's Range5.41 - 5.61
52 Week Range4.34 - 7.66
Volume2,144,717
Avg. Volume2,499,523
Market Cap1.307B
Beta (3Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.44
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.86
Trade prices are not sourced from all markets
  • ACCESSWIRE5 days ago

    Cannabis and Biotech Stocks That Have Run Parabolically

    HENDERSON, NV / ACCESSWIRE / October 11, 2018 / Cannabis and Biotech companies have been receiving increased attention from the street as of late. One particular company that has caught significant attention ...

  • ACCESSWIRE18 days ago

    Today's Research Reports on Trending Tickers: TherapeuticsMD and Endo International

    NEW YORK, NY / ACCESSWIRE / September 28, 2018 / U.S. markets finished higher on Thursday as the jobless claims increase was smaller than expected and second quarter GDP rose 3.1%, marking the best growth ...

  • Business Wire18 days ago

    TherapeuticsMD Announces Multiple Presentations Related to Imvexxy™ and TX-001HR at the 2018 Annual Meeting of the North American Menopause Society

    TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced the schedule of ten oral presentations and posters at NAMS 2018, the annual meeting of the North American Menopause Society being held in San Diego, California on October 3-6, 2018, related to ImvexxyTM and TX-001HR, the Company’s investigational bio-identical hormone therapy combination of estradiol and progesterone in ...

  • Business Wire18 days ago

    TherapeuticsMD Enters Into Label Discussions for TX-001HR

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the Company has entered into discussions with the U.S. Food and Drug Administration (FDA) regarding the proposed label for TX-001HR, the Company’s investigational bio-identical hormone therapy combination of estradiol and progesterone in a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopause. As previously announced, the Prescription Drug User Fee Act (PDUFA) target action date for the completion of the FDA’s review of the new drug application (NDA) for TX-001HR is October 28, 2018. The Company does not anticipate providing subsequent updates with respect to label discussions prior to the PDUFA target action date.

  • Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
    Zacks20 days ago

    Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options

    Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.

  • Business Wire21 days ago

    TherapeuticsMD to Present at 2018 Cantor Global Healthcare Conference

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the company will participate in the 2018 Cantor Global Healthcare Conference being held on October 1-3, 2018. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

  • Business Wire26 days ago

    TherapeuticsMD Announces the FDA has Granted AnnoveraTM Marketing Exclusivity as a New Chemical Entity

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that AnnoveraTM (segesterone acetate and ethinyl estradiol vaginal system) has been granted marketing exclusivity as a new chemical entity (NCE) from the U.S. Food and Drug Administration. TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing novel products exclusively for women. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

  • Business Wirelast month

    TherapeuticsMD Announces Commercial Availability of Imvexxy™ 4 mcg

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced the commercial availability of Imvexxy™ (estradiol vaginal inserts) 4 mcg dose in the United States. Imvexxy 4 mcg is the lowest dose vaginal estrogen product approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

  • Simply Wall St.last month

    What You Must Know About TherapeuticsMD Inc’s (NASDAQ:TXMD) Market Risks

    Anyone researching TherapeuticsMD Inc (NASDAQ:TXMD) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. InvestorsRead More...

  • ACCESSWIRElast month

    High Value Cannabis and Biotech Stocks

    HENDERSON, NV / ACCESSWIRE / September 11, 2018 / A very interesting biotechnology company ENDV (Endonovo Therapeutics, Inc.), has an FDA cleared product, and is flying under the radar. ENDV has been on ...

  • Here's Why TherapeuticsMD Jumped 24.1% in August
    Motley Foollast month

    Here's Why TherapeuticsMD Jumped 24.1% in August

    The pharma company had a busy month of updates and progress.

  • See what the IHS Markit Score report has to say about TherapeuticsMD Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

    TherapeuticsMD Inc NASDAQ/NGS:TXMD

  • Why Invitae Stock Rose 23% in Week Ended August 24
    Market Realist2 months ago

    Why Invitae Stock Rose 23% in Week Ended August 24

    On August 24, Invitae (NVTA) stock closed at $12.56, which represents a ~4.75% growth from its prior day’s close of $11.99. It hit its 52-week high of $12.75 on August 24. For the week ended August 24, Invitae stock closed at $12.56, which represents a ~23% rise from its prior week’s close of $10.21 on August 17. Invitae delivered solid growth in the second quarter of 2018 when it reported revenues of $37.3 million compared to $14.3 million in Q2 2017.

  • See what the IHS Markit Score report has to say about TherapeuticsMD Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

    TherapeuticsMD Inc NASDAQ/NGS:TXMD

  • Business Wire2 months ago

    TherapeuticsMD to Present at 13th Annual Wells Fargo Securities Healthcare Conference

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the company will present at the 13th Annual Wells Fargo Securities Healthcare Conference being held on September 5-6, 2018 in Boston.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of TXMD earnings conference call or presentation 30-Jul-18 12:30pm GMT

    Q2 2018 TherapeuticsMD Inc Earnings Call

  • SmarterAnalyst2 months ago

    Key FDA Decisions Could Power These 3 Biopharma Stocks

    Today, we list 3 biopharma companies that have FDA events approaching along with positive analyst sentiment. In other words, analysts expect these companies' stock prices to appreciate as they draw closer to their respective catalysts. Let's take a closer look at Kala Pharma (NASDAQ:KALA), TherapeuticsMD (NASDAQ:TXMD), and Antares Pharma (NASDAQ:ATRS). Biotech investor anticipation will be high on Friday, August 24, where Kala's Inveltys will be in the spotlight.

  • Benzinga2 months ago

    FDA Approves New Form Of Self-Administered Female Birth Control

    On Friday, TherapeuticsMD Inc (NASDAQ: TXMD) announced FDA approval of the first-ever patient-controlled long-acting reversible vaginal birth control system. What Happened? The new birth control is the first of its kind and is likely to be classified as a “new chemical entity,” which would potentially grant TherapeuticsMD five years of patent exclusivity. “The U.S. contraceptive market is shifting toward long-acting solutions and we believe ANNOVERA represents an exciting new entrant for women and healthcare providers by providing the first woman-controlled, procedure-free, long-acting, reversible birth control product putting the woman in control of both her fertility and menstruation," said Dr. Brian Bernick, Co-Founder of TherapeuticsMD. What’s Next?

  • Business Wire2 months ago

    TherapeuticsMD Announces FDA Approval of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved ANNOVERA™ (segesterone acetate/ethinyl estradiol vaginal system), the first long-acting prescription birth control that is patient-controlled, procedure-free and reversible. The ANNOVERA contraceptive vaginal system is a small, soft flexible ring that prevents ovulation for an entire year (13 cycles) and can be inserted and removed by a woman at her discretion in repeated four-week cycles (remaining in place continuously for three weeks followed by removal for one week).

  • Investopedia2 months ago

    TherapeuticsMD Receives Bullish Note From Street on New Found Potential  

    TherepeuticsMD (NYSE: TXMD), a commercial stage biopharma company focused on women’s health innovation, has seen massive stock price movement in the past few months as it goes through new developments in its service offering. Here we use TipRanks data to take a closer look at what Wall Street’s top analysts see in store for this surging stock over the next 12 months. The primary factor driving bullish sentiments from analysts is the company’s new product, Imvexxy.

  • See what the IHS Markit Score report has to say about TherapeuticsMD Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

    TherapeuticsMD Inc NASDAQ/NGS:TXMD

  • Business Wire2 months ago

    TherapeuticsMD Announces Closing of its Underwritten Public Offering and Concurrent Registered Direct Offering of Common Stock

    TherapeuticsMD, Inc. (TXMD) today announced the closing of its previously announced $65 million underwritten public offering of common stock, at a price to the public of $5.10 per share, and concurrent $20 million registered direct offering of common stock to a strategic investor at a price of $5.10 per share. In connection with the underwritten public offering, TherapeuticsMD granted the underwriters an option to purchase up to an additional 1,911,764 shares of common stock at the public offering price less the underwriting discount, which option was exercised in full and closed. TherapeuticsMD received net proceeds from the offerings of approximately $90.0 million, after deducting underwriting discounts and offering expenses payable by TherapeuticsMD.

  • Business Wire2 months ago

    TherapeuticsMD Announces Pricing of Its Underwritten Public Offering and Concurrent Registered Direct Offering for Aggregate Gross Proceeds of $85 Million

    TherapeuticsMD, Inc. (TXMD) today announced the pricing of its previously announced $65 million underwritten public offering of common stock at a price to the public of $5.10 per share. In addition, TherapeuticsMD has granted to the underwriters of the underwritten public offering an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to an additional 1,911,764 shares of common stock. The gross proceeds to TherapeuticsMD from the offerings are expected to be approximately $85 million, before deducting underwriting discounts, commissions and other offering expenses payable by TherapeuticsMD, assuming no exercise of the underwriters’ option to purchase additional shares of common stock.

  • Business Wire2 months ago

    TherapeuticsMD Licenses Population Council’s Novel Segesterone Acetate/ Ethinyl Estradiol One-Year Vaginal Contraceptive System

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that it has entered into an exclusive license agreement with the Population Council to commercialize its investigational segesterone acetate/ ethinyl estradiol one-year vaginal system for contraception in the United States (U.S.). The one-year vaginal contraceptive system is in the shape of a ring and combines a novel progestin, segesterone acetate (Nestorone®), with a widely used estrogen to prevent ovulation for an entire year (13 cycles). The New Drug Application (NDA) for the one-year vaginal contraceptive system is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date for the completion of the FDA’s review of the NDA of August 17, 2018.

  • Business Wire2 months ago

    Knight Therapeutics and TherapeuticsMD Announce Strategic Partnership

    Knight Therapeutics Inc. (GUD.TO) (“Knight”), a Canadian specialty pharmaceutical company, and TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that they have entered into a licensing agreement that grants Knight the rights to commercialize TX-004HR and TX-001HR in Canada and Israel. TX-004HR is TherapeuticsMD’s FDA-approved product, marketed as Imvexxy™ (estradiol vaginal inserts) in the U.S., for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.